Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese participant~* Age 6 weeks through \<11 weeks (42 to 76 days from date of birth) at Visit 1~Exclusion Criteria:~* History of hypersensitivity and/or anaphylaxis to any of the product ingredients in V260 or DTP-IPV~* Gastrointestinal disorder, growth retardation, or failure to thrive~* History of intussusception~* Untreated congenital gastrointestinal disorder (such as Meckel diverticulum)~* Known or suspected impairment of immunological function, including severe immunodeficiency (SCID)~* Cardiovascular, renal, liver, or blood disease~* History of convulsion~* Undergoing immunosuppressive therapy or living with a close relative with congenital immune deficiency~* Prior vaccination with rotavirus vaccine and/or DTP-IPV vaccine~* Live vaccine received within 28 days or inactivated vaccine received within 7 days~* At high risk for tuberculosis exposure

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 11 Weeks
- Healthy Volunteers: t

Study Arms:
- Concomitant RotaTeq™ and DTP-IPV (Type: EXPERIMENTAL): RotaTeq™ (2 mL oral dose) and DTP-IPV (0.5 mL subcutaneous injection) administered concomitantly at Visit 2 (\>=4 weeks after Visit 1), Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4).
- Staggered RotaTeq™ and DTP-IPV (Type: ACTIVE_COMPARATOR): RotaTeq™ (2 mL oral dose) administered at Visit 1 (Day 1), Visit 3 (6-8 weeks after Visit 1), and Visit 5 (6-8 weeks after Visit 3) and DTP-IPV (0.5 mL subcutaneous injection) administered at Visit 2 (\>=4 weeks after Visit 1), Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4).

Based on this trial design, predict the completion outcome and termination type (if applicable).